UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT NO. 2
on
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 18, 2003
XOMA LTD.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
BERMUDA
--------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
0-14710 52-2154066
(Commission File Number) (IRS Employer Identification No.)
2910 Seventh Street, Berkeley, California 94710
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code (510) 204-7200
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events
As announced on December 18, 2003, Alexion Pharmaceuticals, Inc. and XOMA
Ltd. agreed to collaborate for the development and commercialization of an
antibody to treat chemotherapy-induced thrombocytopenia.
A copy of the agreement governing the collaboration is attached hereto as
Exhibit 2 and incorporated herein by reference.
Item 7. Exhibits
1. Press Release dated December 18, 2003. *
2. Co-Development and Co-Commercialization Agreement, dated as of December 17,
2003, by and between Alexion Pharmaceuticals, Inc. and XOMA (US) LLC (with
certain confidential information omitted, which omitted information is the
subject of a confidential treatment request and has been filed separately
with the Securities and Exchange Commission).
___________________
* Previously filed.
-2-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: March 19, 2004 XOMA LTD.
By: /s/ Christopher J. Margolin
------------------------------
Christopher J. Margolin
Vice President, General
Counsel and Secretary
EXHIBIT INDEX
Number Description
------ -----------
1. Press Release dated December 18, 2003. *
2. Co-Development and Co-Commercialization Agreement, dated as of December 17,
2003, by and between Alexion Pharmaceuticals, Inc. and XOMA (US) LLC (with
certain confidential information omitted, which omitted information is the
subject of a confidential treatment request and has been filed separately
with the Securities and Exchange Commission).
___________________
* Previously filed.